Q3 2024 Management View Revenue for Q3 FY2024 increased 16.6% year-on-year to ¥1,367.6 billion, driven by growth in oncology and international markets. Core operating profit rose 33% to ¥229 billion.

Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from ...

AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities ...

Narrow-moat Daiichi Sankyo’s third-quarter earnings were ... However, it depends on the continued momentum of Enhertu, which remains strong so far. We expect multiple key data readouts this ...

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...

The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...

Japanese drugmaker Daiichi Sankyo has appointed Hiroyuki Okuzawa to succeed Sunao Manabe, as chief executive (CEO), effective ...

In the Japan business unit, sales of Lixiana, a direct oral anticoagulant; Tarlige analgesic; and ENHERTU, an anti-cancer agent increased as did the sales of Daiichi Sankyo Healthcare, while again ...

Analysts flagged concerns over achieving oncology revenue targets amid dependency on ENHERTU’s growth to offset Datroway’s shortfall. Daiichi Sankyo’s Q3 FY2024 results reflect strong ...

Tokyo: Daiichi Sankyo Company, Ltd has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive ...